Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07275606 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1

Study acronym: CABNATE
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 66 to 44 · Study sites: 0 to 1 · Start date changed from estimate of Mar 17, 2026 to Apr 15, 2026v2 Show 3 more changesShow less
    • Enrollment target: 66 to 44
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 17, 2026 to Apr 15, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
Trial Details
NCT Number NCT07275606
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov